博雅生物(300294) - 2023 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2023 was CNY 805,928,136.64, representing a 23.11% increase compared to CNY 654,635,799.08 in the same period last year[19] - The net profit attributable to shareholders for Q1 2023 was CNY 170,317,490.97, a 64.47% increase from CNY 103,554,147.18 year-on-year[19] - The total profit amounted to 205,802,789.13, an increase from 125,762,971.64[45] - Net profit reached 174,373,215.65, compared to 106,852,356.15 in the previous period, reflecting a significant growth[45] - The net profit attributable to the parent company's owners was 170,317,490.97, up from 103,554,147.18[45] - The overall financial performance indicates a robust growth trajectory and improved profitability metrics[45] Cash Flow - The net cash flow from operating activities surged to CNY 222,678,836.22, marking a significant increase of 905.46% compared to CNY 22,146,972.56 in the previous year[19] - Cash received from sales and services increased by 30.39% to 782,399,226.54, primarily due to increased collections[32] - Cash paid for purchasing goods and services rose by 32.06% to 295,808,934.54, mainly due to increased procurement of medical supplies[32] - Investment activities generated a net cash outflow of ¥20,268,839.68, an improvement from a net outflow of ¥712,158,654.56 in the previous period[41] - The company reported a net increase in cash and cash equivalents of ¥179,436,811.37, contrasting with a decrease of ¥690,691,299.91 in the previous period[41] Assets and Liabilities - The total assets at the end of Q1 2023 amounted to CNY 8,196,383,781.60, reflecting a 2.03% increase from CNY 8,033,175,408.45 at the end of the previous year[19] - The total current assets reached CNY 6,239,082,168.98, an increase from CNY 6,073,386,246.99 at the beginning of the year[15] - Total liabilities rose to ¥771,236,715.69 from ¥748,348,858.19 in the previous period, reflecting ongoing financial commitments[43] - The total equity attributable to shareholders increased to ¥7,355,951,977.81, up from ¥7,185,634,486.84 in the previous period, indicating growth in shareholder value[43] Earnings and Expenses - The basic earnings per share for Q1 2023 was CNY 0.34, a 61.90% increase from CNY 0.21 in the same period last year[19] - The diluted earnings per share also stood at CNY 0.34, reflecting the same growth rate of 61.90% compared to CNY 0.21 year-on-year[19] - Operating costs increased by 42.64% to 424,061,104.31, attributed to revenue growth and changes in sales structure[23] - R&D expenses rose by 45.32% to 9,984,394.66, driven by increased investment in blood product research[23] - Income tax expenses were 31,429,573.48, up from 18,910,615.49, indicating higher tax obligations[45] Other Financial Metrics - The company reported a significant increase in non-recurring gains and losses amounting to CNY 32,502,159.86 after tax for the current period[22] - Accounts receivable decreased by 100.00% to 0.00, primarily due to the expiration of commercial acceptance bills[23] - Prepayments decreased by 33.84% to 6,389,963.81, mainly due to the write-off of prepayments for goods received[23] - Fair value changes in investment income surged by 518.81% to 34,757,152.48, resulting from changes in the fair value of financial products and merger fund investments[23] - The company reported a significant increase in net profit from continuing operations, maintaining a strong performance[45]